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Association Between Leukocyte Telomere Length and the Risk of
Incident Atrial Fibrillation: The Framingham Heart Study
Laila Staerk, MD; Biqi Wang, PhD; Kathryn L. Lunetta, PhD; Robert H. Helm, MD; Darae Ko, MD; Jason A. Sherer, MD; Patrick T. Ellinor, MD,
PhD; Steven A. Lubitz, MD, PhD; David D. McManus, MD; Ramachandran S. Vasan, MD; Emelia J. Benjamin, MD, ScM; Ludovic Trinquart,
MPH, PhD
Background-—Advancing age is a prominent risk factor for atrial ﬁbrillation (AF). Shorter telomere length is a biomarker of
biological aging, but the link between shorter telomere length and increased risk of AF remains unclear. We examined the
association between shorter leukocyte telomere length (LTL) and incident AF.
Methods and Results-—We included AF-free participants from the observational Framingham Heart Study Offspring cohort from
1995 to 1998, who had LTL measurements. We examined the association between baseline LTL and incident AF with multivariable
Cox models adjusted for age, sex, current smoking, height, weight, systolic and diastolic blood pressure, use of antihypertensive
medication, diabetes mellitus, history of myocardial infarction, and history of heart failure. The study sample comprised 1143
AF-free participants (52.8% women), with mean age of 608 years. The mean LTL at baseline was 6.950.57 kb. During
15.14.2 years mean follow-up, 184 participants (64 women) developed AF. Chronological age was associated with increased risk
of AF (hazard ratio per 10-year increase, 2.16; 95% conﬁdence interval, 1.71–2.72). There was no signiﬁcant association between
LTL and incident AF (hazard ratio per 1 SD decrease LTL, 1.01; 95% conﬁdence interval, 0.86–1.19). Our study was observational in
nature; hence, we could not exclude residual confounding and we were unable to establish causal pathways.
Conclusions-—In our moderate-sized community-based cohort, we did not ﬁnd evidence for a signiﬁcant association between LTL
and risk of incident AF. ( J Am Heart Assoc. 2017;6:e006541. DOI: 10.1161/JAHA.117.006541.)
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I t is estimated that among persons ≥40 years of age, 1out of 4 will develop atrial ﬁbrillation (AF).1–4 The
prevalence of AF increases with advancing age,5,6 and with
an aging population, the prevalence of AF in United States has
been projected to rise from 3 to 7 million in 2015 to
between 6 and 12 million in 2050.7,8 AF imposes a burden on
the patient and healthcare system, because AF is associated
with diminished quality of life and increased risk of chronic
kidney disease, dementia, stroke, myocardial infarction, heart
failure, sudden cardiac death, and all-cause mortality.9,10
Numerous modiﬁable and nonmodiﬁable AF risk factors have
been identiﬁed and incorporated in AF risk prediction
models,5,11 and age has been recognized as the most
prominent risk factor for AF.5
Aging is a complicated process involving multiple biological
changes related with time; therefore, age may be perceived as
chronological and biological. Chronological age is determined
by time passed since birth, whereas biological age involves
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molecular and cellular processes. Telomere length has been
proposed as a potential biomarker of biological aging.12 As
depicted in Figure 1, telomeres are the cap structure of
chromosome ends, which function to protect the chromo-
some from deterioration. A telomere comprises repetitive
DNA sequences. The speciﬁc sequence of nucleotides in
human telomeres is 50-TTAGGG-30, which is repeated about
2000 to 2500 times. During cell division, telomere shortening
occurs in the process of DNA replication; hence, numerous
cell divisions will shorten the telomere length and reﬂect
changes in biological age.13
Shorter telomere length is associated with a wide range of
age-related chronic diseases, such as hypertension, insulin
resistance, vascular dementia, myocardial infarction, and
stroke.14–18 Only a few studies have investigated the
association between shorter telomere length and the age-
related disease AF, and the studies reported opposing results
with only 1 study supporting the association.19–21
Theoretically, there may be a possible pathophysiological
mechanism linking shorter telomere length and AF, as
illustrated in Figure 1. The development of AF may involve
a vulnerable atrial substrate, because of ﬁbrosis or
inﬂammation, for example.22 Shorter telomere length has
been linked to ﬁbrosis, inﬂammation, and collagen deposi-
tion in other diseases (eg, idiopathic pulmonary ﬁbrosis),
and may play a similar role in pathological atrial structure
remodeling.23–25 Oxidative stress not only affects mito-
chondrial DNA mutations and shortened telomere
length,26,27 but also may play a role for the development
of atrial substrate.27,28 A trigger is required to initiate AF; a
highly hypothetical relationship has been drawn between
shorter telomere length and autonomic nervous system
dysregulation, high sympathetic activation, and high heart
rate.23 However, the pathophysiological mechanisms poten-
tially underlying the association between shorter telomere
length and AF are unknown.
Figure 1. Conceptual ﬁgure illustrating possible mechanisms between shortening of telomere length and
atrial ﬁbrillation.
Clinical Perspective
What Is New?
• Chronological aging is a strong predictor of incident atrial
ﬁbrillation, but leukocyte telomere length shortening is not a
major predictor of incident atrial ﬁbrillation.
What Are the Clinical Implications?
• There is a potential for using biomarkers as predictors of
atrial ﬁbrillation, but the evidence points in a direction that
shorter telomere length may not be a suitable biomarker to
predict atrial ﬁbrillation.
DOI: 10.1161/JAHA.117.006541 Journal of the American Heart Association 2
Telomere Length and Incident Atrial Fibrillation Staerk et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 26, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
In the present investigation, we hypothesized that shorter
leukocyte telomere length (LTL) is associated with increased
risk of incident AF.
Methods
Study Sample
The Framingham Heart Study enrolled the Original cohort in
1948. The Offspring cohort (n=5124) was enrolled in 1971
and comprised adult children of the Original cohort and their
spouses. The Offspring cohort was followed up every 4 to
8 years with standardized Framingham Heart Study examina-
tions.29 Participants were eligible for the present study if they
attended their routine sixth examination cycle (n=3532),
which occurred between 1995 and 1998. The inclusion day
was the day the participant attended the sixth examination
cycle. The exclusion criteria for the present study were as
follows: age <45 years, AF prevalent at inclusion, and missing
participant characteristics at inclusion (Figure 2).
Measurement of Leukocyte Telomere Length
All participants provided written informed consent for genetic
research. Based on laboratory tests from the sixth examination
cycle, DNA was extracted from leukocytes. LTL was measured
if participants had sufﬁcient available buffy coat (Data S1 and
Figure S1). Southern blotting was performed to obtain the
mean length of the terminal restriction fragment, as previously
described.30 The mean length of the terminal restriction
fragment is referred to as LTL. The coefﬁcient of variation of
the LTL measurement for duplicate or triplicate DNA samples
was 2.4% on different gels. The laboratory personnel perform-
ing the LTL measurement were blinded to clinical character-
istics of the Framingham Heart Study participants.
Clinical Evaluation at Baseline
A clinical evaluation was performed at inclusion. We collected
variables used for the Cohorts for Heart and Aging Research
in Genomic Epidemiology-AF consortium (CHARGE-AF) risk
model for the prediction of incident AF11: age, sex, height,
weight, current smoking (deﬁned as smoking cigarettes
regularly during the year before inclusion), systolic blood
pressure, diastolic blood pressure, antihypertensive medica-
tion, diabetes mellitus (deﬁned as fasting glucose ≥126 mg/
dL or use of insulin or hypoglycemic medication), history of
myocardial infarction, and history of heart failure.
Assessment of AF and Follow-Up
Incident AF through December 31, 2014 was the outcome of
interest. AF was assessed from Framingham Heart Study
examinations, and participants’ outside clinical visits or
hospitalizations; questions about AF status were included in
3532 participants from Framingham Heart Study Offspring cohort attending Exam 6
Excluded
1943 without LTL measurement
345 inadequate quality or amount of DNA for LTL measurement
1244 participants with LTL measurement
Excluded
54 with age <45 years
39 with AF prevalent at inclusion day
8 where data on baseline characteristics were missing
1143 AF-free participants with LTL measurement in final study sample
Figure 2. Flow diagram depicting the selection of the study sample. AF indicates atrial ﬁbrillation; LTL,
leukocyte telomere length.
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health history updates. In the Framingham Heart Study, 2
medical doctors evaluated all available records and ECGs of
incident AF. AF was deﬁned as atrial ﬂutter or ﬁbrillation. Each
included participant was followed from the day of sixth
examination cycle until whichever came ﬁrst: newly diagnosed
AF, or last Framingham Heart Study examination or last health
history contact, in which the participant was free of AF, death,
or end of follow-up in year 2014.
Association Between Leukocyte Telomere Length
and Incident AF
The LTL measurements were normally distributed and there-
fore logarithmic transformations of the measurements were
not applied. The association of LTL with incident AF was
assessed using Cox proportional hazards regression models.
We analyzed LTL as a continuous variable. We ﬁrst adjusted the
model for age and sex; we ﬁtted a second model further
adjusted for smoking, height, weight, systolic blood pressure,
diastolic blood pressure, antihypertensivemedication, diabetes
mellitus, history of myocardial infarction, and history of heart
failure. The results were expressed as the hazard ratio (HR)
associated with 1 SD unit decrease in LTL. We veriﬁed the
proportional hazards assumption in the Cox model with respect
to LTL, by using a predictor-by-time interaction term (P=0.96).
To illustrate the results graphically, we estimated multivariable-
adjusted Kaplan–Meier curves to show the adjusted cumulative
risk of AF across 3 groups deﬁned according to LTL tertiles
(short=5.4–6.7, medium=6.8–7.2, or long LTL=7.3–8.7). The
adjustment was achieved with inverse probability weighting
and we used the R package IPWsurvival.31
In sensitivity analyses, (1) we excluded participants with
history of myocardial infarction or heart failure; (2) age
(instead of calendar time) was used as the time scale in the
Cox models32; and (3) we calculated the subdistribution HRs
using the Fine and Gray model to account for the competing
risk of death. Lastly, we explored the functional form (beyond
linearity) between LTL and the hazard of incident AF by using
fractional polynomials and splines. Analyses involved use of R
version 3.3.2 (R Development Core Team, Vienna, Austria).
We conducted post hoc analysis testing for sex and age as
effect modiﬁers of the association between LTL and AF. In the
latter, age was analyzed as a continuous variable and we
plotted the marginal effect associated with a 1 SD decrement
in LTL across the range of age 45 to 85 years; we also
reported a stratiﬁed analysis with age categorized into age
<60 and age ≥60 years.
Statistical Power and Minimal Detectable Effect
The proportion of participants experiencing incident AF in the
study sample was 16% (184/1143). For a type I error of 0.05,
we estimated that, with power of 80%, the minimally
detectable HR was about 1.25 per 1 SD decrease in LTL.
We considered a 2-sided P value of <0.05 as statistically
signiﬁcant.
Ethics
The study was approved by the Framingham Heart Study
review committee.
Results
Study Sample Characteristics
The selection of participants is illustrated in Figure 2; after
exclusions, we studied 1143 AF-free participants. The char-
acteristics of the study sample at inclusion (time participant
attended sixth examination cycle during 1995–1998) are
shown in Table 1. The mean age was 609 years, 52.8%
were women, and 1 out of 3 participants used antihyper-
tensive medications. The mean LTL was 6.950.57 kb. The
baseline characteristics of the study sample did not differ
systematically from participants who did not have LTL
measurements (Table S1). Figure S2 depicts a scatterplot of
LTL against age, and a linear regression model showed that
the mean LTL was associated with 0.22-kb decrease per
10-year higher mean chronological age.
Association Between Leukocyte Telomere Length
and Incident AF
The mean follow-up was 15.14.2 years. During follow-up, a
total of 184 participants (35% women) developed incident AF,
Table 1. Characteristics of the Study Population at Baseline
Characteristic n=1143
Age, y 60.08.6
Women, % 604 (52.8)
Leukocyte telomere length, kb 6.950.57
Height, cm 1689
Weight, kg 7917
Current smoker, % 158 (13.8)
Systolic blood pressure, mm Hg 13019
Diastolic blood pressure, mm Hg 769
Treatment for hypertension, % 339 (29.7)
Diabetes mellitus, % 128 (11.2)
History of myocardial infarction, % 32 (2.8)
History of heart failure, % 5 (0.4)
Data are meanSD for continuous traits and n (%) for dichotomous traits.
DOI: 10.1161/JAHA.117.006541 Journal of the American Heart Association 4
Telomere Length and Incident Atrial Fibrillation Staerk et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 26, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
and 262 participants died free of AF. The main results are
shown in Table 2. Chronological age was strongly associated
with AF (multivariable HR per 10-year increment in age, 2.16;
95% conﬁdence interval [CI], 1.71–2.72). With adjustment for
sex only, LTL was associated with incident AF (HR associated
with a 1 SD decrease in LTL, 1.30; 95% CI, 1.12–1.52). In the
multivariable-adjusted Cox regression, we did not ﬁnd evi-
dence for an association between LTL and incident AF (HR
associated per 1 SD decrease in LTL, 1.01; 95% CI, 0.86–
1.19).
In Figure 3, we show the multivariable-adjusted cumulative
risk of incident AF in 3 groups deﬁned according to LTL
tertiles. Participants with longer LTL did not have higher
probability of being free of AF in follow-up compared with
those with shorter LTL.
Sensitivity Analyses
Table 3 includes the sensitivity analyses. Excluding partici-
pants with history of myocardial infarction or heart failure did
not substantially change the results compared with the main
models depicted in Table 2. Similarly, using age as a time
scale model showed results similar to the main results,
indicating that the adjustment for age was acceptable in the
main analysis. Analyses taking the competing risk of death
into account (Table S2) did not show any statistically
signiﬁcant association between LTL and incident AF either
(subdistribution HR, 0.99; 95% CI, 0.84–1.17).
Post Hoc Analyses
We did not observe signiﬁcant effect modiﬁcation by sex
(P=0.45), but we found a signiﬁcant qualitative interaction
between LTL and age (P=0.03; Figure S3). In stratiﬁed
analyses, the HR associated with 1 SD decrease of LTL was
0.80 (95% CI, 0.60–1.08) in participants <60 years and 1.21
(95% CI, 0.67–1.48) in those ≥60 years. Lastly, Figure S4
illustrates a smoothing spline ﬁt for the relative hazard of
incident AF as a function of LTL. The graph does not support a
nonlinear relationship between hazards of LTL and incident AF
(P=0.15 for the nonlinear term).
Discussion
In our prospective study examining the relation of LTL
measurements to incident AF in the Framingham Heart Study,
we have several principal ﬁndings. First, we did not observe a
statistically signiﬁcant association between lower mean or
categorical LTL and incident AF. Second, in the multivariable-
adjusted model, the association between chronological age
and incident AF was positive, which suggests that chronolog-
ical age was a stronger predictor of AF than biological age, as
assessed by LTL. In Table 4, we have summarized the
evidence before our study, the added value of our study,
and the implications of the published evidence.
Another longitudinal study by Roberts et al also examined
the association between telomere length and incident AF.20
The study was performed with data from the Cardiovascular
Health Study, which is a population-based cohort study with
Medicare-participants from 4 different communities in the
United States. In total, 1639 participants were included in the
study by Roberts et al, and mean age was 72.2 years and
mean LTL measurement 6.33 kb. In our study, the mean age
was lower and the mean LTL length longer. As in our study,
Roberts et al found no association between LTL shortening
and incident AF when LTL shortening was examined as both a
continuous variable and across tertiles. Categorization of
continuous predictors may create a loss of power and residual
confounding33; in our study we explored whether a linear
association would not accurately represent the relationship
between LTL and the hazard of incident AF, and we did not
ﬁnd support for a nonlinear association (Figure S3). The
studies by Roberts et al and our group considered telomere
length from circulating leukocytes. However, Roberts et al
also had measurements of left atrial cell telomere length from
35 participants, who had undergone cardiac surgery, and in
comparison they reported that atrial telomere length was
statistically longer than circulating LTL (P=0.03). The atrial
tissue observation was found among participants with and
without AF, and the ﬁnding supported that shorter telomere
length and increased risk of AF may not be correlated. Similar
to our study, Roberts et al tested the strength of telomere
shortening and chronological age, and they also concluded
that chronological aging was a stronger predictor of AF than
telomere length as a biomarker for biological aging.20
In contrast to the ﬁndings in the longitudinal studies by
Roberts et al and our group, a cross-sectional study by
Carlquist et al found a stepwise positive association between
telomere shortening categorized according to quintiles.
Among the 3576 included participants with an available LTL
measurement from the Intermountain Heart Collaborative
Study, 379 had prevalent AF. The mean age was 69.8, 68.4,
and 72.2 years in the paroxysmal, persistent, and permanent
groups, respectively. The prevalence of AF was 11.6% in the
shortest LTL group to 7.8% in the longest LTL group
Table 2. Association of LTL Shortening and Incident AF
Age- and Sex-Adjusted Multivariable-Adjusted*
HR (95% CI)† P Value HR (95% CI)† P Value
LTL 1.06 (0.90–
1.25)
0.48 1.01 (0.86–
1.19)
0.90
AF indicates atrial ﬁbrillation; CI, conﬁdence interval; LTL, leukocyte telomere length.
*Covariates included age, sex, height, weight, smoking, systolic blood pressure, diastolic
blood pressure, antihypertensive medication, diabetes mellitus, history of myocardial
infarction, and history of heart failure.
†HR=hazard ratio associated with a decrease in LTL of 1 SD (0.57 kb).
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(P<0.0001). However, this stepwise reduction in LTL and
increased risk of AF was less apparent between the 3 middle
quintiles. Among AF cases, Carlquist et al were able to
classify the subtype of AF in 277 participants; they reported
that the presence of paroxysmal AF was more strongly
associated with LTL shortening than the presence of persis-
tent and permanent AF. It has long been held that AF
progresses from paroxysmal to a more persistent subtype.34
The ﬁnding by Carlquist et al was surprising, since theoret-
ically one would anticipate that a stepwise LTL shortening
would occur from paroxysmal to persistent or permanent AF.
However, diverse measurement methods of telomere length,
variations between longitudinal versus cross-sectional data,
and measuring telomere length as a linear or categorical
variable (eg, tertiles or quintiles) may inﬂuence the results in
the different studies. Moreover, the study by Carlquist et al
did not include longitudinal follow-up. Finally, the included
participants were all referred for angiography and a large
percentage of the participants had coronary heart disease.
Coronary heart disease is a risk factor for AF5,6; hence, the
ﬁndings in the study by Carlquist et al may have been
affected by selection bias.
Shorter telomere length and risk of cardiovascular disease
was assessed in a meta-analysis performed by Haycock
et al.18 Based on multivariable-adjusted studies, the meta-
analysis reported an increased relative risk of coronary heart
disease and cerebrovascular disease comparing the shortest
third versus the longest third of telomere length. However, the
association between cerebrovascular disease and shorter
telomere length did not persist in subgroup analyses including
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Figure 3. Multivariable-adjusted Kaplan–Meier curves depict the cumulative risk of atrial ﬁbrillation
across 3 groups deﬁned according to LTL tertiles: short LTL (5.42–6.66 kb), medium LTL (6.67–7.2 kb),
and long LTL (7.3–8.7 kb). The cumulative risk estimates are adjusted for age, sex, smoking, height, weight,
systolic blood pressure, diastolic blood pressure, antihypertensive medication, diabetes mellitus, history of
myocardial infarction, and history of heart failure. LTL indicates leukocyte telomere length.
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only prospective or high-quality studies. The meta-analysis did
not examine the association between shortening telomere
length and risk of AF. As illustrated in Figure 1, a relationship
between shorter telomere length and incident AF is theoret-
ically possible, but the relationship was not evident in our
primary analyses. We found an interaction between LTL and
age in a post hoc analysis. As illustrated in Figure 1, a
relationship between shorter telomere length and incident AF
is potentially possible in older adults. However, the relation-
ship was not evident in our primary analyses, so we must
consider the ﬁnding hypothesis generating. Future studies on
the interaction between age and telomeres and risk of AF will
need larger study samples to clarify whether there is a subtle
relationship between shorter telomere length and incident AF
in older adults.
Strengths and Limitations
The major strength of our study was the use of prospective
data from the Framingham Heart Study, which has previously
been used for LTL analyses.15,30,35 However, our study also
had several limitations. First, this was an observational study;
therefore, we cannot rule out residual confounding, establish
causality, or provide mechanistic explanations. Second, we
were not able to distinguish between atrial ﬂutter or
ﬁbrillation and AF subtypes. Third, we acknowledge that we
may have missed some AF cases in our study in the absence
of continuous cardiac rhythm monitoring. Another possible
reason for missing AF cases was that those who developed AF
might have stopped attending Framingham Heart Study
examinations, though we attempted to obtain their outside
records regardless of attendance. Fourth, telomere attrition
evolves with time, and we were not able to assess time-
dependent effects of LTL, because we only measured LTL at a
single examination. However, telomere attrition over time is
an important issue; accumulation of major life stressors
predicts telomere shortening, whereas healthy behavior gives
protection against major life stressors’ effect on telomere
attrition.36,37 Moreover, telomere length was measured in
circulating leukocytes. Because the deterioration rate and
telomere length differ between cell types, it would have been
superior to measure the telomere length in cardiomyocytes
Table 4. Findings in Context
Evidence before this study:
We searched MEDLINE up to March 10, 2017 for observational studies that assessed the association between telomere length and incident atrial fibrillation
(“Telomere Shortening”[Mesh] OR “Telomere”[Mesh] OR telomere[tiab]) AND (“Atrial Fibrillation”[Mesh] OR “atrial fibrillation”[tiab]). Three previous studies
have examined the association between shorter telomere length and risk of atrial fibrillation. The 3 studies were designed differently and reported conflicting
results, with only 1 study supporting an association between shorter telomere length and atrial fibrillation
Added value of our study:
Our observational study based on data from Framingham Heart Study did not support an association between shorter leukocyte telomere length and incident atrial
fibrillation. The findings of our study are consistent with the observation that chronological aging is a strong predictor of incident atrial fibrillation, but leukocyte
telomere length shortening is not a major predictor of incident atrial fibrillation
Implications of all the available evidence:
There is a potential for using biomarkers as predictors of atrial fibrillation, but the evidence points in a direction that shorter telomere length may not be a suitable
biomarker to predict atrial fibrillation
Table 3. Sensitivity Analyses for the Association of LTL Shortening and Incident AF
Exclusion of Participants With a History of Myocardial Infarction and Heart Failure
Age- and Sex-Adjusted Multivariable-Adjusted*
HR (95% CI)† P Value HR (95% CI)† P Value
LTL 1.10 (0.93–1.30) 0.27 1.06 (0.89–1.26) 0.50
Age Used as Time Scale
Sex-Adjusted Multivariable-Adjusted‡
HR (95% CI)† P Value HR (95% CI)† P Value
LTL 1.05 (0.90–1.23) 0.54 0.99 (0.84–1.17) 0.92
AF indicates atrial ﬁbrillation; CI, conﬁdence interval; HR, hazard ratio; LTL, leukocyte telomere length.
*Covariates included age, sex, height, weight, smoking, systolic blood pressure, diastolic blood pressure, antihypertensive medication, diabetes mellitus, history of myocardial infarction,
and history of heart failure.
†Hazard ratio associated with a decrease in LTL of 1 SD (0.57 kb).
‡Same covariates as above, except for age (controlled for as the time scale).
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instead of circulating leukocytes. However, in an observa-
tional community-based study it is not feasible to measure
cardiomyocyte telomere length, which is a limitation. We also
acknowledge that the exact amount of sufﬁcient buffy coat
was unspeciﬁed in the protocol. Another limitation was that
the participants in the lowest LTL tertile group were more
likely to be lost to follow-up or to die. It is likely that our post
hoc subgroup analysis with participants age ≥60 years lacks
statistical power for an association of smaller magnitude.
Finally, the Framingham Heart Study participants were largely
middle-aged to older adults of European ancestry, and the
generalizability of our ﬁndings to individuals of non-European
ancestry and other ages is unknown.
Conclusions
In our observational study based on data from 1143
participants from the Framingham Heart Study with LTL
measurements, there was no signiﬁcant association between
shorter telomere length and risk of incident AF.
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Data S1.  
 
Protocol for leukocyte telomere length analysis by the terminal restriction fragment length 
(TRFL analysis) 
A major problem with the leukocyte telomere length (LTL) analysis is that the DNA may migrate at 
slightly different rates in different regions of the gel. This is due to a host of technical reasons. For 
this reason, we have developed techniques that resolved each digested DNA sample and the 
molecular weight ladder on the same lane, thereby eliminating the effect of variation in DNA 
migration in different lanes. Samples are digested overnight with restriction enzymes digest set, 
HinfI (5.2 U)/Rsa I (5.2 U) (Roche). DNA samples (3 µg each) and DNA ladders (1 kb DNA ladder 
plus 23.1kb fragment of λ DNA/Hind III fragments (Invitrogen, Carlsbad, CA)) are resolved on a 
0.5% agarose gel (20 cm x 20 cm) at 50 V (GNA-200 Pharmacia Biotech). After 16 hr, the DNA is 
depurinated for 15 min in 0.25 N HCl, denatured 30 min in 0.5 mol/L NaOH/1.5 mol/L NaCl and 
neutralized for 30 min in 0.5 mol/L Tris, pH 8/1.5 mol/L NaCl. The DNA is transferred for 1 hr to a 
positively charged nylon membrane (Roche) using a vacuum blotter (Boeckel Scientific, 
Feasterville, PA). The membranes are spotted at 4 sites with diluted telomeric probe [digoxigenin 
3’-end labeled 5’-(CCTAAA)3] (arrows, Figure 1A, B ,C) and  then hybridized at 65oC with the 
probe overnight in 5 x SSC, 0.1% Sarkosyl, 0.02% SDS and 1% blocking reagent (Roche). The 
membranes are washed 3 times at room temperature in 2 x SSC, 0.1% SDS each for 15 min and 
once in 2 x SSC for 15 min. The digoxigenin-labeled probe is detected by the digoxigenin 
luminescent detection procedure (Roche) and exposed on X-ray film. After scanning the LTL signal 
by densitometry (Figure S1A), the membranes are stripped and re-probed with a molecular weight 
marker probe (Figure S1B). The superimposition of A and B, using the 4 spotted sites of telomeric 
probe (arrows), yields the image shown in Figure S1C. In this way, variation in DNA migrations in 
different lanes minimally affects the analysis. 
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Table S1. Characteristics of participants with and without leukocyte telomere length 
measurements at examination cycle 6 
 
 
Without LTL 
measurement* 
(n=1973) 
With LTL 
measurement 
(n=1143) p value 
Age (years) 608.7 60.08.6 0.79 
Women (%) 1083 (54.9) 604 (52.8) 0.29 
Height (cm) 1679.6 1689 0.007 
Weight (kg) 78.017.1 7917 0.17 
Current smoker (%) 310 (15.7) 158 (13.8) 0.17 
Systolic blood pressure (mmHg) 12919 13019 0.02 
Diastolic blood pressure (mmHg) 769 769 0.52 
Treatment for hypertension (%) 569 (28.8) 339 (29.7) 0.66 
Diabetes mellitus (%) 186 (9.4) 128 (11.2) 0.13 
History of myocardial infarction (%) 64 (3.2) 32 (2.8) 0.56 
History of heart failure (%) 15 (0.8) 5 (0.4) 0.39 
 
Data are mean (standard deviation) for continuous traits and n (%) for dichotomous traits.  
* In total, 2288 participants did not have LTL measurements done; of these 2288 we excluded those 
with age <45 years (n=180), AF prevalent at inclusion day (n=72), and missing data at time of 
inclusion (n=63). Among the 1973 participants without LTL measurement, 339 developed incident 
AF during follow up. 
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Table S2. Association of leukocyte telomere length and incident atrial fibrillation, when taking 
the competing risk of death into account 
 
 Age- and sex-adjusted  Multivariable-adjusted* 
 HR (95% CI)† P value  HR (95% CI) † P value 
Leukocyte telomere length  1.02 (0.87-1.20) 0.78  0.99 (0.84-1.17) 0.92 
 
* Covariates included age, sex, height, weight, smoking, systolic blood pressure, diastolic blood 
pressure, anti-hypertensive medication, diabetes mellitus, history of myocardial infarction, and 
history of heart failure. 
† Subdistribution hazard ratio associated with a decrease in LTL of 1 standard deviation (0.57 
kilobase), estimated with a Fine and Gray model. 
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Figure S1. Illustration of an autoradiogram showing the terminal restriction fragments 
(LTLs) (A), the molecular weight ladders (B) and the superimposition of A and B 
 
 
The position of each band of the MW ladder (y) a is determined by y= a0+a1*exp
(-kb/a2). 
The mean LTL length is calculated as follows: LTL =∑ODi/∑(ODi/MWi), where ODi is optical 
density at a given position in the lane and MWi is molecular weight at that position. This formula 
accounts for the fact that longer telomeres bind more labeled probe and consequently appear darker 
on the X-ray film.  
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Figure S2. Scatter plot of leukocyte telomere length against age at baseline 
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Figure S3. Marginal effect for incident atrial fibrillation associated with a 1 SD decrement in 
of leukocyte telomere length across the range of age 45-85 years  
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Figure S4. Smoothing spline fit showing the relationship between relative hazard of incident 
atrial fibrillation and leukocyte telomere length. 
 
 
Median LTL = 7 was used as reference. p value = 0.15 for a non-linear term 
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